ALTAMIRA THERAPEUTICS LTD (CYTO) Forecast, Price Target & Analyst Ratings

NASDAQ:CYTO • BMG0360L1349

Current stock price

0.3 USD
-0.11 (-25.94%)
At close:
0.262 USD
-0.04 (-12.67%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALTAMIRA THERAPEUTICS LTD (CYTO).

Forecast Snapshot

Consensus Price Target

Price Target
$5.41
+ 1,702.00% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.86%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$5.41
Upside
+ 1,702.00%
From current price of $0.30 to mean target of $5.41, Based on 7 analyst forecasts
Low
$5.35
Median
$5.41
High
$5.57

Price Target Revisions

1 Month
0.00%
3 Months
-35.44%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for CYTO. The average price target is 5.41 USD. This implies a price increase of 1702% is expected in the next year compared to the current price of 0.3.
The average price target has been revised downward by 35.44% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CYTO Current Analyst RatingCYTO Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

CYTO Historical Analyst RatingsCYTO Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.86%
CYTO was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CYTO.
In the previous month the buy percentage consensus was at a similar level.
CYTO was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2024 - 2026

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2021 2022 2023 2024 2025 2026
Revenue
YoY % growth
CYTO revenue by date.CYTO revenue by date.
60K310K
416.67%		188.233K
-39.28%
-100.00%		5.835M
EBITDA
YoY % growth
CYTO ebitda by date.CYTO ebitda by date.
-13.18M
-150.57%		-12.68M
3.79%		-1.876M
85.20%		N/AN/AN/A
EBIT
YoY % growth
CYTO ebit by date.CYTO ebit by date.
-13.26M
-151.14%		-12.8M
3.47%		-1.995M
84.41%		-9.106M
-356.34%		-11.778M
-29.35%		-8.297M
29.56%
Operating Margin
CYTO operating margin by date.CYTO operating margin by date.
-22,100.00%-4,129.03%-1,060.03%N/AN/A-142.19%
EPS
YoY % growth
CYTO eps by date.CYTO eps by date.
N/AN/AN/A-2.70-1.19
55.85%		-1.64
-37.61%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CYTO Yearly Revenue VS EstimatesCYTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2026 1M 2M 3M 4M 5M
CYTO Yearly EPS VS EstimatesCYTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2024 2025 2026 -1K -2K -3K -4K

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-4.65%
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
214.13%
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ALTAMIRA THERAPEUTICS LTD / CYTO Forecast FAQ

Can you provide the average price target for ALTAMIRA THERAPEUTICS LTD stock?

7 analysts have analysed CYTO and the average price target is 5.41 USD. This implies a price increase of 1702% is expected in the next year compared to the current price of 0.3.

How do analysts rate ALTAMIRA THERAPEUTICS LTD (CYTO)?

The consensus rating for ALTAMIRA THERAPEUTICS LTD (CYTO) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.